With a market capitalization (market cap) of $42.8B — a measure of how much the company is worth — Haleon plc is the 370th most valuable company in Healthcare as of August 18, 2026. Shares trade at $9.72, up +1.41% on the day.
of 2,587
price ÷ annual EPS
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
Haleon plc is a significant global entity in the consumer healthcare sector, engaging in the entire process from scientific research and development to the production and worldwide distribution of various wellness goods. The company's reach extends across North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific region. Its diverse product portfolio encompasses therapeutic solutions for oral care, pain management, respiratory well-being, and digestive health, alongside a comprehensive range of vitamins, minerals, and other dietary supplements. Noteworthy brands within its collection include Panadol, Voltaren, Advil, Otrivin, Theraflu, Sensodyne, Polident, parodontax, and Centrum. Established in 2021, the company was initially known as DRVW 2022 plc before officially changing its name to Haleon plc in February 2022. It is headquartered in Brentford, United Kingdom.
Visit websiteAs of August 18, 2026, Haleon plc (HLN) is worth $42.8B — this is its market capitalization, the total value of all its outstanding shares.
Haleon plc’s market cap is $42.8B, which ranks it #370 among the most valuable companies in the Healthcare sector tracked on MarketCapLens.
Haleon plc (HLN) shares trade at $9.72, up 1.46% on the day, as of August 18, 2026.
Haleon plc trades at a price-to-earnings (P/E) ratio of 27.0, based on its latest share price and annual earnings per share.
Fundamentals are annual. Figures labeled with their fiscal year.
FY 2025